<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>PTEN hamartoma tumor syndromes, including Cowden syndrome</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">PTEN hamartoma tumor syndromes, including Cowden syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">PTEN hamartoma tumor syndromes, including Cowden syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter P Stanich, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Maegan E Roberts, MS, CGC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">J Thomas Lamont, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Benjamin A Raby, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert G Voigt, MD, FAAP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H5356445"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Germline pathogenic variants in the phosphatase and tensin homolog (<em>PTEN</em>) gene have been described in a variety of rare syndromes with different clinical presentations that are collectively known as PTEN hamartoma tumor syndromes (PHTS). The defining clinical feature of PHTS is the presence of hamartomatous tumors, which are disorganized growths of native cells in native tissues. PHTS is inherited in an autosomal dominant fashion.</p><p class="headingAnchor" id="H2181235516"><span class="h1">PHENOTYPIC SPECTRUM OF PHTS</span><span class="headingEndMark"> — </span>Once thought to be distinct genetic syndromes, the different clinical presentations of PHTS illustrate the heterogenous clinical spectrum and phenotypic overlap associated with germline <em>PTEN</em> pathogenic variants. The phenotypic spectrum of PHTS includes the following entities:</p><p class="bulletIndent1"><span class="glyph">●</span>Cowden syndrome (also known as Cowden disease or multiple hamartoma syndrome) is the best-described phenotype within PHTS. Besides multiple hamartomas in a variety of tissues, patients have characteristic dermatologic manifestations such as trichilemmomas, oral fibromas, and punctate palmoplantar keratoses, and an increased risk of breast, endometrial, thyroid, kidney, and colorectal cancers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bannayan-Riley-Ruvalcaba syndrome is another rare subset of PHTS. In addition to hamartomas, these patients have multiple subcutaneous lipomas, macrocephaly, and penile lentigines  (<a class="graphic graphic_picture graphicRef62253" href="/z/d/graphic/62253.html" rel="external">picture 1</a>). High penetrance of cancer, as reported in Cowden syndrome, has not been as clearly documented, but is presumed to be present.</p><p></p><p class="bulletIndent1">Genotype analyses have concluded that a similar spectrum of pathogenic variants in the <em>PTEN</em> gene is found in the Bannayan-Riley-Ruvalcaba syndrome as in other PHTS, leading to the conclusion that they are related allelic disorders [<a href="#rid1">1-3</a>]. Both conditions are now considered phenotypically distinct, age-related presentations of a similar genetic abnormality [<a href="#rid4">4,5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adult Lhermitte-Duclos disease is characterized by hamartomatous outgrowths of the cerebellum (cerebellar dysplastic gangliocytoma) and has also been associated with <em>PTEN</em> pathogenic variants [<a href="#rid6">6,7</a>]. This syndrome may arise in conjunction with Cowden syndrome or without other signs of PHTS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two other conditions have been associated with <em>PTEN</em> pathogenic variants and, although they lack hamartomas, some argue that they should be incorporated into the definition of PHTS:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A Proteus-like syndrome with a distinct type of epidermal nevus (also referred to as segmental overgrowth, lipomatosis, arteriovenous malformation, and epidermal nevus [SOLAMEN)] syndrome or type 2 segmental Cowden syndrome) that likely relates to the early loss of heterozygosity at the <em>PTEN</em> allele in the affected tissues in patients with an underlying germline <em>PTEN</em> pathogenic variant [<a href="#rid8">8-10</a>]. (See <a class="local">'Proteus-like syndrome'</a> below and  <a class="medical medical_review" href="/z/d/html/13726.html" rel="external">"Capillary malformations (port wine birthmarks) and associated syndromes", section on 'Proteus syndrome'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Autism spectrum disorders with macrocephaly [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/z/d/html/2849.html" rel="external">"Macrocephaly in infants and children: Etiology and evaluation", section on 'Anatomic megalencephaly'</a>.)</p><p></p><p>This topic review will review the major clinical syndromes that are associated with <em>PTEN</em> pathogenic variants and are considered part of the spectrum of PHTS.</p><p class="headingAnchor" id="H462459902"><span class="h1">COWDEN SYNDROME</span><span class="headingEndMark"> — </span>Cowden syndrome was first reported in 1963; an autosomal dominant pattern of inheritance was first suggested in 1972 and later confirmed [<a href="#rid12">12-14</a>]. It is estimated that the rate of de novo<em> </em>pathogenic variants is likely 10 to 30 percent [<a href="#rid15">15</a>].</p><p>Although data are limited, the estimated prevalence of Cowden syndrome is 1 in 200,000 to 250,000 [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H17510999"><span class="h2">Molecular genetics</span><span class="headingEndMark"> — </span>The <em>PTEN</em> gene is a negative regulator of the phosphoinositide-3-kinase (PI3K)-AKT and the mechanistic (previously called mammalian) target of rapamycin (mTOR) signaling pathways, which are critical for cell proliferation, cell cycle progression, and apoptosis [<a href="#rid17">17</a>]. Loss of function of this gene contributes to oncogenesis, and somatic mutations are frequently identified in various malignancies. As a result, the <em>PTEN</em> gene, which is located on chromosome 10q23 [<a href="#rid18">18</a>], is considered to be a tumor suppressor gene [<a href="#rid19">19-21</a>].</p><p>Germline pathogenic variants in <em>PTEN</em> are found in many patients meeting clinical diagnostic criteria for Cowden syndrome [<a href="#rid22">22</a>]. Although it was initially reported that up to 83 percent of individuals meeting clinical criteria had a detectable <em>PTEN</em> pathogenic variant [<a href="#rid3">3</a>], this was an overestimate attributable to the highly selected nature of earlier Cowden syndrome cohorts. More recent estimates are that germline <em>PTEN</em> pathogenic variants are found in approximately 20 to 34 percent of individuals who meet clinical criteria for Cowden syndrome or who meet criteria for genetic testing [<a href="#rid23">23,24</a>]. Most pathogenic variants are unique to a given family. (See <a class="local">'Diagnostic criteria'</a> below.)</p><p>Genetic testing for Cowden syndrome is discussed below. (See <a class="local">'Testing for pathogenic variants'</a> below.)</p><p>Allelic heterogeneity has been observed in Cowden syndrome, with the majority of those found to have a <em>PTEN</em> pathogenic variant identified via sequence analysis and the minority being identified found to have a large deletion or duplication. The pathogenicity of <em>PTEN</em> promoter variants (c.-959 to c.-822), however, is less clear, with more recent data suggesting no association with Cowden syndrome [<a href="#rid25">25,26</a>]. (See <a class="local">'Testing for pathogenic variants'</a> below.)</p><p>There is also limited but inconclusive evidence of locus heterogeneity, with alterations reported at other loci:</p><p class="bulletIndent1"><span class="glyph">●</span>In some patients with features of Cowden syndrome who lack <em>PTEN</em> pathogenic variants, hypermethylation of the promoter of the KILLIN gene (<em>KLLN</em>), leading to reduced expression of <em>KLLN</em>, has been described [<a href="#rid27">27</a>]. Patients with <em>KLLN</em> gene promoter hypermethylation were said to have a higher risk of breast and renal cancer than those with <em>PTEN</em> pathogenic variant-positive disease [<a href="#rid27">27</a>]. The clinical utility of this finding is unknown. The <em>KLLN</em> gene, which is located on chromosome 10q23 and functions as a p53-regulated inhibitor of DNA synthesis, shares the same transcription site as the <em>PTEN</em> gene [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other Cowden-like patients have been reported with pathogenic variants in the succinate dehydrogenase (<em>SDH</em>) gene, subunits B and D [<a href="#rid27">27,29-31</a>]. However, others have disputed this association, pointing out that the majority of the <em>SDH</em> variants identified appear to be polymorphisms rather than pathogenic variants [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Germline <em>PIK3CA </em>and<em> </em>v-akt murine thymoma viral oncogene homolog 1 (<em>AKT1</em>)<em> </em>variants have also been reported in a small number of phenotypic Cowden-like patients without <em>PTEN</em>,<em> SDH</em>,<em> </em>or<em> KLLN </em>mutations in one report [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Variants in the S cerevisiae, B homolog (<em>SEC23B)</em> gene have been associated with Cowden syndrome in a single family [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A heterozygous germline epidermal growth factor receptor (<em>EGFR</em>) pathogenic variant was found by exome sequencing in a 41-year old with Lhermitte-Duclos syndrome [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some patients who have the Cowden syndrome phenotype but who lack germline <em>PTEN</em> mutations have germline gain of function variants in the WW domain-containing protein 1 (<em>WWP1</em>) gene, which encodes an E3 ubiquitin ligase that negatively regulates the function of PTEN [<a href="#rid36">36</a>]. A study of patients with multiple colon polyps who also had some features of Cowden syndrome (but did not meet clinical diagnostic criteria and did not have detectable <em>PTEN </em>germline pathogenic variants) found germline gain of function variants in the <em>WWP1</em> gene in a small number of patients (4 percent, 5 out of 126 subjects) [<a href="#rid37">37</a>]. The clinical significance of this is unknown at this point.</p><p></p><p class="headingAnchor" id="H462459910"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>Historically, the published data on clinical manifestations have come mainly from small case series or compilations of published cases, most of which predated the development of consensus criteria for diagnosis and genetic testing for Cowden syndrome. More recently, data have been published on several larger cohorts of patients identified through genetic testing programs, but these suffer from significant ascertainment bias [<a href="#rid23">23,38-40</a>]. As a result, the true frequencies of the clinical features of Cowden syndrome are not known [<a href="#rid41">41</a>]. (See <a class="local">'Diagnostic criteria'</a> below.)</p><p>The range of clinical manifestations of Cowden syndrome includes hamartomatous tumors in multiple organ systems, both mucocutaneous and extracutaneous, and an increased risk for malignancy (including second malignant neoplasms [<a href="#rid42">42</a>]).</p><p class="headingAnchor" id="H462459918"><span class="h3">Mucocutaneous</span><span class="headingEndMark"> — </span>Skin and oral findings are a distinctive and common manifestation of Cowden syndrome; they are often the initial finding that leads to the diagnosis. Although commonly noticed in the second decade of life, the age of onset may vary from 4 to 75 years [<a href="#rid13">13,43</a>]. The prevalence of mucocutaneous abnormalities in patients with Cowden syndrome was thought to be close to 100 percent based upon early case series, but this may be an overestimate based upon prevalence data driven by genetic testing [<a href="#rid13">13,23,44,45</a>].</p><p>The common lesions are trichilemmomas, acral keratoses, and facial papules/oral papillomas:</p><p class="bulletIndent1"><span class="glyph">●</span>Trichilemmomas  (<a class="graphic graphic_picture graphicRef60952" href="/z/d/graphic/60952.html" rel="external">picture 2</a>) are hamartomatous tumors of the outer root sheath of the hair follicle or other skin appendages that occur on the face and neck of patients with Cowden syndrome. Trichilemmoma is a clinically significant sign of Cowden syndrome when seen in multiplicity (three or more). They present as wart-like, skin-colored papules with slightly rough surfaces; histologically, the lesions contain large glycogen-rich cells [<a href="#rid46">46</a>]. Clinically, trichilemmomas are indistinguishable from trichoepitheliomas and other benign follicular tumors affecting the pilosebaceous unit, including fibrofolliculomas and trichodiscomas (which are characteristic lesions of Birt-Hogg-Dube syndrome) [<a href="#rid47">47</a>]. At least one lesion should be biopsied given the difficulty with clinical diagnosis [<a href="#rid48">48</a>]. (See  <a class="medical medical_review" href="/z/d/html/100661.html" rel="external">"Birt-Hogg-Dubé syndrome"</a>.)</p><p></p><p class="bulletIndent1">A trichilemmoma is rarely a sporadic feature. One study found a complete loss of PTEN expression by immunohistochemistry in five of six (83 percent) trichilemmomas from patients with Cowden syndrome compared with only 1 of 33 (3 percent) sporadic trichilemmomas [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/z/d/html/7606.html" rel="external">"Cutaneous manifestations of internal malignancy", section on 'Heritable conditions associated with skin disorders and malignancy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acral keratoses present as 1 to 4 mm keratotic verrucous papules that are located on the dorsal hands, wrists, or feet. Patients can also develop translucent punctate keratoses on the palms or soles [<a href="#rid13">13,43,50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Facial papules are the most frequent lesions and are found in up to 86 percent of cases [<a href="#rid51">51</a>]. They have a predilection for periorificial regions, sometimes extending into the nostrils. Oral papules and papillomas (coalesced papules) on the lips, buccal mucous membranes or palate are pink or white smooth lesions of 1 to 4 mm in diameter. When they coalesce, they can form a distinctive cobblestone appearance  (<a class="graphic graphic_picture graphicRef80290" href="/z/d/graphic/80290.html" rel="external">picture 3</a>) [<a href="#rid46">46,50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multiple other histologies have been reported occasionally (eg, clear cell acanthomas [<a href="#rid52">52</a>]), so consideration of PHTS is warranted in the context of multiple different types of cutaneous lesions in a family or individual.</p><p></p><p>The differential diagnosis of the mucocutaneous findings includes tuberous sclerosis, Gardner syndrome, epidermodysplasia verruciformis, Brooke-Spiegler syndrome [<a href="#rid53">53</a>], neurofibromatosis type I, and multiple fibrofolliculomas (Birt-Hogg-Dubé syndrome) [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/z/d/html/6175.html" rel="external">"Tuberous sclerosis complex: Clinical features"</a> and  <a class="medical medical_review" href="/z/d/html/2948.html" rel="external">"Hereditary kidney cancer syndromes"</a> and  <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/15509.html" rel="external">"Epidermodysplasia verruciformis"</a>.)</p><p>There have been case reports to suggest that melanoma may be associated with Cowden syndrome [<a href="#rid54">54,55</a>]. More recently, <em>PTEN</em> pathogenic variant carriers have been projected to have an 8.5-fold greater risk when compared with the average population and a 6 percent lifetime risk [<a href="#rid38">38</a>]. Another study found similar risks, noting an elevated standardized incidence ratio (SIR) for melanoma (SIR 6.3, 95% CI 3.5-10.5) with an estimated 5 percent lifetime risk [<a href="#rid56">56</a>]. However, an international study of <em>PTEN</em> pathogenic variant carriers did not find an increased frequency of melanoma [<a href="#rid57">57</a>]. Additional studies are necessary to clarify this risk before melanoma can be considered a clinical feature of PHTS [<a href="#rid48">48</a>]. (See <a class="local">'Diagnostic criteria'</a> below.)</p><p class="headingAnchor" id="H462459926"><span class="h3">Breast</span><span class="headingEndMark"> — </span>Breast cancer is the most common malignancy in Cowden syndrome, although overall, germline pathogenic variants in <em>PTEN</em> are rare causes of a genetic predisposition to breast cancer [<a href="#rid58">58</a>]. For example, no <em>PTEN</em> pathogenic variants were reported among 1781 individuals (1750 women) referred for commercial breast cancer susceptibility gene (<em>BRCA</em>) testing because of a diagnosis of breast cancer [<a href="#rid59">59</a>]. (See  <a class="medical medical_review" href="/z/d/html/785.html" rel="external">"Overview of hereditary breast and ovarian cancer syndromes"</a>.)</p><p>The lifetime risk of breast cancer for affected female patients is frequently reported at between 25 and 50 percent [<a href="#rid38">38,40,41,60</a>], although more recent reports project a cumulative risk as high as 81 to 91 percent [<a href="#rid38">38,39,56,57,61</a>]. These, however, suffer from ascertainment biases. The onset of breast cancer is often early, with a diagnosis at a mean of 38 to 46 years of age [<a href="#rid41">41,60</a>]. Although there are several rare reports of breast cancer in male patients with Cowden syndrome, the association is unproven [<a href="#rid62">62,63</a>]. (See  <a class="medical medical_review" href="/z/d/html/779.html" rel="external">"Breast cancer in men"</a>.)</p><p>Based on limited information, the malignant breast tumors in women are usually ductal in origin and are often surrounded by densely collagenized hamartomatous lesions, suggesting that the tumor arose from areas of hamartomatous change within the breast [<a href="#rid60">60</a>]. There may be a tendency towards more aggressive disease in patients with Cowden syndrome:</p><p class="bulletIndent1"><span class="glyph">●</span>An increased incidence of both multifocality and bilateral involvement has been observed for both benign and malignant breast disorders.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a report of 46 patients who presented to the Mayo Clinic over a 30-year period and who met only clinical diagnostic criteria for PHTS, five of the six breast cancers in this cohort were triple-negative (estrogen receptor, progesterone receptor, and HER2-negative) [<a href="#rid64">64</a>]. However, among 1824 women with triple-negative breast cancer not selected for any family history criteria, only one person was found to have a pathogenic <em>PTEN</em> variant [<a href="#rid65">65</a>]. Among women with pathogenic <em>PTEN</em> variants who developed breast cancer, only 3 of 19 were triple negative, suggesting the clinical criteria include women with other etiologies [<a href="#rid66">66-68</a>]. (See  <a class="medical medical_review" href="/z/d/html/14227.html" rel="external">"ER/PR negative, HER2-negative (triple-negative) breast cancer"</a>.)</p><p></p><p>Approximately 50 percent of women with Cowden syndrome have benign breast conditions such as ductal hyperplasia, intraductal papillomatosis, adenosis, lobular atrophy, fibroadenomas, fibrocystic change, and densely fibrotic hyalinized nodules [<a href="#rid13">13,51,60</a>]. However, the reported frequencies of these conditions are nearly identical to those reported in the general population, and a systematic review concluded that there was insufficient evidence to include benign breast disease as a diagnostic criterion [<a href="#rid48">48</a>]. (See <a class="local">'Diagnostic criteria'</a> below and  <a class="medical medical_review" href="/z/d/html/806.html" rel="external">"Overview of benign breast diseases", section on 'Miscellaneous benign lesions of the breast'</a>.)</p><p class="headingAnchor" id="H462459934"><span class="h3">Thyroid</span><span class="headingEndMark"> — </span>The most frequently reported extracutaneous manifestation of Cowden syndrome is thyroid disease, occurring in over one-half of patients [<a href="#rid69">69</a>]. Benign thyroid abnormalities such as multinodular goiter, lymphocytic (Hashimoto) thyroiditis, and adenomas are very common and reported in up to 68 percent of patients [<a href="#rid13">13,69-71</a>]. (See  <a class="medical medical_review" href="/z/d/html/7890.html" rel="external">"Diagnostic approach to and treatment of thyroid nodules", section on 'History and physical examination'</a>.)</p><p>According to one estimate, individuals with Cowden syndrome have an approximately 70-fold increased incidence of non-medullary thyroid cancer relative to the general population [<a href="#rid72">72</a>]. The reported risk of thyroid cancer in affected individuals ranges from 3 to 38 percent in large case series [<a href="#rid38">38-41,45,56,57,64,70,72</a>]. The median age at diagnosis was 35 in one case series, which is younger than the general population based on Surveillance, Epidemiology, and End Results data [<a href="#rid73">73</a>]. (See  <a class="medical medical_review" href="/z/d/html/7860.html" rel="external">"Papillary thyroid cancer: Clinical features and prognosis", section on 'Family history'</a>.)</p><p>Notably, there are multiple reports of thyroid cancer diagnosed in children as young as age seven [<a href="#rid54">54,72,74,75</a>]. Children presenting with non-medullary thyroid cancer should be tested for <em>PTEN</em> pathogenic variants. (See <a class="local">'Testing for pathogenic variants'</a> below and  <a class="medical medical_review" href="/z/d/html/5835.html" rel="external">"Thyroid nodules and cancer in children", section on 'Genetic predisposition'</a>.)</p><p>In most series, papillary neoplasms predominate. However, follicular thyroid cancer may be over-represented compared with the general population [<a href="#rid48">48,72</a>].</p><p class="headingAnchor" id="H462459942"><span class="h3">Genitourinary</span><span class="headingEndMark"> — </span>Several genitourinary lesions, including endometrial cancer and renal cell cancer (RCC), may arise in patients with Cowden syndrome:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benign</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Benign uterine abnormalities such as uterine fibroids are common findings in female patients. A systematic review concluded that it was not clear that these rates represented an increase over that expected in the general population and that there was insufficient evidence to include uterine fibroids as a diagnostic criterion [<a href="#rid48">48</a>]. (See <a class="local">'Diagnostic criteria'</a> below and  <a class="medical medical_review" href="/z/d/html/15676.html" rel="external">"Uterine fibroids (leiomyomas): Variants and smooth muscle tumors of uncertain malignant potential", section on 'Cowden syndrome'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Men with Cowden syndrome may have multiple bilateral hyperechoic testicular lesions on ultrasound; they represent lipomatosis of the testes [<a href="#rid76">76-78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malignant</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The risk of endometrial cancer is elevated in female patients, with a reported cumulative lifetime risk of 13 to 30 percent [<a href="#rid23">23,38,40,45,56,57</a>]. There are rare reports of endometrial cancer occurring in adolescents as young as age 14 [<a href="#rid79">79</a>]. (See  <a class="medical medical_review" href="/z/d/html/3249.html" rel="external">"Endometrial carcinoma: Epidemiology, risk factors, and prevention", section on 'Other potential heritable factors'</a> and  <a class="medical medical_review" href="/z/d/html/16924.html" rel="external">"Endometrial carcinoma: Clinical features, diagnosis, prognosis, and screening", section on 'Patients with Cowden syndrome'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>RCC is also increased in individuals with <em>PTEN</em> pathogenic variants. In large case series of patients with <em>PTEN</em> mutations, RCC was reported in 2 to 5 percent [<a href="#rid23">23,24,39</a>]. Some project a 13 to 34 percent cumulative lifetime risk of RCC, but this may reflect an overestimate due to ascertainment bias [<a href="#rid38">38-40,56,64</a>]. There is also a suggestion that papillary histology may be more common than expected [<a href="#rid80">80</a>]. (See  <a class="medical medical_review" href="/z/d/html/2948.html" rel="external">"Hereditary kidney cancer syndromes"</a>.)</p><p></p><p class="headingAnchor" id="H5646167"><span class="h3">Gastrointestinal</span></p><p class="headingAnchor" id="H3262046"><span class="h4">Esophageal glycogen acanthosis</span><span class="headingEndMark"> — </span>Glycogenic acanthosis of the esophagus typically appears as multiple, uniformly sized gray-white round elevations in an otherwise normal-appearing mucosa, usually in the midportion of the esophagus  (<a class="graphic graphic_picture graphicRef117128" href="/z/d/graphic/117128.html" rel="external">picture 4</a>) [<a href="#rid81">81</a>]. The exact frequency of esophageal glycogen acanthosis is unclear, but in one report, diffuse dozens or scores of lesions were observed in 8 of 10 patients with Cowden syndrome who underwent evaluation [<a href="#rid82">82</a>]. Although usually clinically irrelevant, when present in conjunction with hamartomatous GI tract polyps, further work-up for Cowden syndrome should occur. (See  <a class="medical medical_review" href="/z/d/html/2253.html" rel="external">"Benign lesions of the esophagus", section on 'Glycogen acanthosis'</a>.)</p><p class="headingAnchor" id="H3262082"><span class="h4">Gastric and duodenal polyps</span><span class="headingEndMark"> — </span>Polyps have been reported throughout the GI tract among <em>PTEN</em> pathogenic variant carriers, with 66 to 100 percent of affected individuals reported to have gastric or duodenal polyps [<a href="#rid45">45,82,83</a>]. Polyp histologies include hamartomas, hyperplastic polyps, ganglioneuromas, adenomas, and inflammatory polyps. Interestingly, there is a report of significant regression of gastric polyps in a Cowden syndrome patient after eradication of <em>Helicobacter pylori</em> [<a href="#rid84">84</a>]. There are rare case reports of gastric cancer [<a href="#rid85">85,86</a>] and duodenal carcinoma [<a href="#rid87">87</a>], but these have not been found to be common in larger case series.</p><p class="headingAnchor" id="H232666187"><span class="h4">Colon polyps</span><span class="headingEndMark"> — </span>The prevalence of colon polyps among <em>PTEN</em> pathogenic variant carriers is as high as 95 percent of those undergoing colonoscopy [<a href="#rid45">45,83,88,89</a>]. The histologic spectrum is diverse. Hamartomatous and inflammatory polyps are the most prevalent, but ganglioneuromas, adenomas, leiomyomas, lipomas, and hyperplastic polyps can also be found. Many patients have multiple synchronous histologic types of polyps [<a href="#rid45">45,88,90</a>]. (See  <a class="medical medical_review" href="/z/d/html/15805.html" rel="external">"Juvenile polyposis syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/2594.html" rel="external">"Overview of colon polyps", section on 'Hamartomatous polyps'</a> and  <a class="medical medical_review" href="/z/d/html/2594.html" rel="external">"Overview of colon polyps", section on 'Inflammatory polyps'</a>.)</p><p class="headingAnchor" id="H232666202"><span class="h4">Colorectal cancer</span><span class="headingEndMark"> — </span>An increased risk of early onset colorectal cancer has been reported in patients with Cowden syndrome:</p><p class="bulletIndent1"><span class="glyph">●</span>A Japanese series found a 9 percent prevalence of colon cancer, a remarkable finding in view of the low rates of colorectal cancer in this population [<a href="#rid83">83</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a series of <em>PTEN</em> pathogenic variant carriers, 13 percent of patients undergoing screening colonoscopy were found to have colorectal adenocarcinomas; all were under the age of 50 (average age 44.4, range 35 to 49) [<a href="#rid45">45</a>]. In a report from the same group of 368 <em>PTEN</em> pathogenic variant-positive patients, the risk of colorectal cancer was estimated at 10-fold higher than the general population, with an estimated lifetime risk of 9 percent [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A multinational series of 156 patients with germline <em>PTEN </em>pathogenic variants found an 18 percent risk of colorectal cancer by the age of 60 [<a href="#rid91">91</a>].</p><p></p><p>It remains unclear whether colonic malignancy arises from adenomatous polyps or whether it can also arise from hamartomatous polyps. Because of these associations, guidelines suggest that <em>PTEN</em> pathogenic variant carriers undergo routine endoscopic surveillance. (See <a class="local">'Management'</a> below.)</p><p class="headingAnchor" id="H462459958"><span class="h3">Neurologic</span></p><p class="headingAnchor" id="H1789401800"><span class="h4">Neuroimaging features</span><span class="headingEndMark"> — </span>The main neuroimaging features associated with Cowden syndrome are Lhermitte-Duclos disease (dysplastic gangliocytoma of the cerebellum), increased white matter volume, enlarged corpus callosum and cerebellum, ventriculomegaly, dilated perivascular spaces, and cavernous malformations [<a href="#rid92">92</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumors and vascular malformations</strong> — A wide range of brain tumors has been purportedly linked to <em>PTEN</em> pathogenic variants [<a href="#rid93">93</a>]. Dysplastic gangliocytoma of the cerebellum, or adult Lhermitte-Duclos disease, refers to a hamartomatous tumor of the cerebellar cortex that can occur in the setting of a <em>PTEN</em> pathogenic variant and Cowden syndrome in adults [<a href="#rid6">6,7</a>]. This histologically benign entity is reported to develop in 6 to 32 percent of Cowden syndrome patients, with the lower estimate derived from a case series that did not include specific imaging of the head, and the upper estimates projected from cohorts with likely ascertainment biases [<a href="#rid40">40,45,94</a>]. Symptoms arise secondary to mass effect in the posterior fossa and commonly include headache, nausea and vomiting, ataxia, and papilledema [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent1">Dysplastic gangliocytoma of the cerebellum can be familial or sporadic. It remains unclear whether all familial cases, even without features of Cowden syndrome, are caused by germline <em>PTEN</em> pathogenic variants, and whether somatic <em>PTEN</em> pathogenic variants occur in sporadic cases; this should be further clarified as genetic testing becomes more readily available [<a href="#rid96">96</a>].</p><p></p><p class="bulletIndent1">Many consider that dysplastic gangliocytoma of the cerebellum is a defining feature of Cowden syndrome [<a href="#rid6">6,41,97</a>]. However, a systematic review concluded that although adult onset Lhermitte Duclos disease had a stronger association with PHTS than pediatric cases, there was insufficient evidence to consider it a pathognomonic criterion [<a href="#rid48">48</a>]. (See <a class="local">'Diagnostic criteria'</a> below.)</p><p></p><p class="bulletIndent1">The Pilarski-revised clinical diagnostic criteria for PHTS include dysplastic gangliocytoma of the cerebellum as a major criterion  (<a class="graphic graphic_table graphicRef91666" href="/z/d/graphic/91666.html" rel="external">table 1</a>) [<a href="#rid48">48</a>]. If diagnosed outside of a known PHTS kindred, affected patients should be thoroughly investigated for other manifestations of Cowden syndrome and considered for <em>PTEN</em> germline testing [<a href="#rid98">98</a>]. (See <a class="local">'Pilarski et al diagnostic criteria'</a> below.)</p><p></p><p class="bulletIndent1">In addition to dysplastic gangliocytoma of the cerebellum, one study found intracranial vascular malformations such as venous and cavernous angiomas in 30 percent of asymptomatic patients who underwent screening magnetic resonance imaging (MRI) [<a href="#rid94">94</a>], and there is a case report of multiple intracranial arteriovenous fistulas in a person with Cowden syndrome [<a href="#rid99">99</a>]. However, this has not been commonly reported [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1">Meningiomas have also been reported in patients with Cowden syndrome [<a href="#rid41">41,94</a>]; however, the data are insufficient to conclude whether they are associated with Cowden syndrome or not [<a href="#rid48">48</a>]. (See  <a class="medical medical_review" href="/z/d/html/5220.html" rel="external">"Epidemiology, pathology, clinical features, and diagnosis of meningioma", section on 'Other schwannomatoses'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Macrocephaly</strong> – Macrocephaly, defined as an occipital-frontal head circumference greater than the 97<sup>th</sup> percentile (greater than two standard deviations above the mean for a given age, sex, and gestation), has historically been reported in 21 to 38 percent of patients with Cowden syndrome [<a href="#rid13">13,51</a>]. At the time, however, it was not routinely assessed, and more recent studies note macrocephaly in 152 of 181 (94.4 percent) patients with confirmed <em>PTEN</em> pathogenic variants, with a mean occipital-frontal circumference 60 cm in adult females and 62.8 cm in adult males (3.5 standard deviations over the general population) [<a href="#rid100">100</a>]. Children with an increased brain size (anatomic megalencephaly) and clinical manifestations consistent with PHTS should be referred for <em>PTEN</em> testing. (See <a class="local">'Diagnostic criteria'</a> below and  <a class="medical medical_review" href="/z/d/html/2849.html" rel="external">"Macrocephaly in infants and children: Etiology and evaluation", section on 'Anatomic megalencephaly'</a> and  <a class="medical medical_review" href="/z/d/html/2849.html" rel="external">"Macrocephaly in infants and children: Etiology and evaluation", section on 'Other tests'</a>.)</p><p></p><p class="headingAnchor" id="H462459974"><span class="h4">Intellectual disability, developmental delay, and autism</span><span class="headingEndMark"> — </span>Intellectual disability or developmental delay has been reported in 12 to 20 percent of Cowden syndrome/PHTS patients [<a href="#rid51">51,101</a>]. Autism (typically with macrocephaly) has also been reported in conjunction with Cowden syndrome/PHTS [<a href="#rid102">102,103</a>]. A more recent study suggests that individuals with Cowden syndrome/PHTS and neurodevelopmental delays may have higher lifetime cancer risks [<a href="#rid56">56</a>]. (See <a class="local">'Autism spectrum disorders and macrocephaly'</a> below.)</p><p class="headingAnchor" id="H10806403"><span class="h3">Immune dysregulation</span><span class="headingEndMark"> — </span>Immune dysregulation (including defects in T and B cell homeostasis, autoimmunity, intestinal lymphoid hyperplasia, thymus hyperplasia, and thymoma as well as T-cell lymphoma) has been described in mice with heterozygous <em>PTEN </em>deletions, and murine models confirm a functional role for PTEN/PI3K signaling pathways in a broad variety of cell types including B cell subsets [<a href="#rid104">104,105</a>]. Data suggest that PTEN deficiency in humans is associated with immune dysregulation that can be manifest as autoimmunity/tissue inflammation and lymphoid hyperplasia [<a href="#rid106">106,107</a>], but the clinical implications for these observations in humans carrying germline <em>PTEN</em> mutations are unclear.</p><p class="headingAnchor" id="H462459982"><span class="h2">Diagnostic criteria</span></p><p class="headingAnchor" id="H938521087"><span class="h3">International Cowden Consortium diagnostic criteria</span><span class="headingEndMark"> — </span>The first modern diagnostic criteria for Cowden syndrome/PHTS were crafted by an international group of experts labeled the International Cowden Consortium in 1996 and updated in 2000 [<a href="#rid108">108,109</a>].</p><p>The specificity of the early Consortium criteria is lower than initially estimated, with only approximately 20 to 34 percent of individuals meeting these clinical criteria having germline <em>PTEN</em> pathogenic variant [<a href="#rid23">23,24</a>]. This has led to efforts to develop more robust criteria for <em>PTEN</em> genetic testing.</p><p class="headingAnchor" id="H462459990"><span class="h3">Pilarski et al diagnostic criteria</span><span class="headingEndMark"> — </span>Alternative clinical diagnostic criteria have been proposed by a multi-center United States group and based upon an updated systematic review of the literature  (<a class="graphic graphic_table graphicRef91666" href="/z/d/graphic/91666.html" rel="external">table 1</a>) [<a href="#rid48">48</a>]. These diagnostic criteria have now been adopted by the National Comprehensive Cancer Network (NCCN) [<a href="#rid110">110</a>]. One of the main differences from the International Cowden Consortium guidelines is that they demoted the dermatologic manifestations from pathognomonic findings to major criteria and included GI hamartomas and penile pigmentation as major criteria. Several features were also added as minor criteria, including autism spectrum disorders, colon cancer, glycogenic acanthosis of the esophagus, and testicular lipomatosis. They found insufficient evidence to support the inclusion of benign breast disease, uterine fibroids, or genitourinary malformations as minor diagnostic criteria.</p><p>There are major and minor criteria, and an operational diagnosis in an individual with no prior family history of Cowden syndrome/PHTS requires either three or more major criteria (one of which must be macrocephaly, Lhermitte-Duclos disease, or GI hamartomas) or two major plus three minor criteria.</p><p>The following criteria permit an operational diagnosis of Cowden syndrome/PHTS in a family in which one individual meets the revised clinical diagnostic criteria or has a <em>PTEN</em> pathogenic variant:</p><p class="bulletIndent1"><span class="glyph">●</span>Any two major criteria with or without minor criteria; or</p><p class="bulletIndent1"><span class="glyph">●</span>One major and two minor criteria; or</p><p class="bulletIndent1"><span class="glyph">●</span>Three minor criteria</p><p></p><p>To assess the revised criteria, 48 individual patients with known <em>PTEN</em> pathogenic variants and sufficient clinical information were analyzed, and 44 (91.6 percent) met the new diagnostic criteria.</p><p>We recommend using the Pilarski et al diagnostic criteria at this point, although further confirmation of the high positive and negative predictive values for <em>PTEN</em> pathogenic variants is needed. These criteria are based upon updated evidence and are less reliant on expert opinion than the International Cowden Consortium diagnostic criteria. In addition, it has a simplified schema using only major and minor criterion that we find easier to navigate.</p><p class="headingAnchor" id="H1141267284"><span class="h2">Testing criteria</span><span class="headingEndMark"> — </span>Testing criteria for Cowden syndrome/PHTS are available from the NCCN (as part of their genetic risk assessment for breast, ovarian, and pancreatic cancer, but not colorectal cancer) [<a href="#rid110">110</a>] that have been adapted to include updated clinical criteria  (<a class="graphic graphic_table graphicRef72070" href="/z/d/graphic/72070.html" rel="external">table 2</a>) [<a href="#rid24">24</a>] (see <a class="local">'Pilarski et al diagnostic criteria'</a> above).</p><p>NCCN guidelines include consideration of germline testing for pathogenic or likely pathogenic <em>PTEN</em> variants identified on somatic tumor profiling [<a href="#rid110">110</a>]. As somatic <em>PTEN</em> variants are common, germline testing should only be considered in patients with Cowden syndrome/PHTS features in the personal or family history. For patients meeting any NCCN Cowden syndrome/PHTS testing criteria, it is recommended that the patient undergo pre- and post-test genetic counseling alongside germline <em>PTEN</em> testing. If a familial <em>PTEN</em> pathogenic variant has not been previously established, consideration should be given to initially testing the family member with the highest likelihood of having a <em>PTEN</em> pathogenic variant based upon the clinical presentation. (See  <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">"Genetic testing"</a>.)</p><p>The NCCN criteria are not refined for pediatric populations, and they do not provide quantitative estimates as to the probability of testing positive for a <em>PTEN</em> pathogenic variant [<a href="#rid110">110</a>]. A clinical scoring system has been developed to help select adult and pediatric patients for <em>PTEN</em> pathogenic variant testing that may have improved sensitivity and specificity compared with the NCCN criteria [<a href="#rid24">24</a>]. The adult prediction model involves demographic data such as sex and age, personal history of cancer, as well as weighted scores for dermatologic, neurologic, breast, gynecologic, GI, endocrine, and genitourinary manifestations. The pediatric criteria are derived from the presence of macrocephaly and either autism or developmental delay, dermatologic findings, vascular abnormalities, or GI polyps. A clinical calculator is available online (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.lerner.ccf.org%2Fgmi%2Fccscore%2F&amp;token=%2FIWsE0N4PYYTvlNDBVg8QEjt6qRgDv%2BtFXlF91lo1Q68BwFo2GWhTjjv8KijysVE&amp;TOPIC_ID=16543" target="_blank">CCF score for PTEN test</a>). Although use of this calculator has been shown to be a cost-effective method for determining if a patient should undergo germline <em>PTEN</em> testing, it needs independent validation prior to widespread adoption [<a href="#rid111">111</a>].</p><p class="headingAnchor" id="H462460007"><span class="h3">Testing for pathogenic variants</span><span class="headingEndMark"> — </span><em>PTEN</em> germline testing, including sequence analysis of the entire coding region and deletion/duplication analysis, is available from multiple clinical laboratories [<a href="#rid97">97</a>]. The majority of <em>PTEN</em> pathogenic variants are detected by sequencing, but all types of pathogenic variants have been reported, including missense, truncating (nonsense/frameshift), and splice site variants as well as insertions and deletions [<a href="#rid3">3,29,30</a>]. Variants have also been reported in the <em>PTEN</em> promoter, and a test for variants in this region of the gene has become clinically available. At present, however, these promoter variants are classified as variants of uncertain significance by most commercial labs based on lack of supportive data for pathogenicity. Several reports from clinical testing laboratories have also questioned the clinical relevance of these variants [<a href="#rid25">25,26</a>]. Current clinical testing is predominantly done as part of a next generation sequencing panel.</p><p>Although the clinical utility and applicability of potential results are still unclear, clinical testing is also available for other genes that have been reported to be associated with a Cowden-like presentation, including <em>AKT1</em>, <em>KLLN</em>, <em>PIK3CA</em>, <em>SDH </em>subunit B, and <em>SDH</em> subunit D. The clinician may look up specific test availability in clinically approved molecular genetics diagnostic laboratories at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryNPgji1PaJ6Kbd%2Fo1hE9A6&amp;TOPIC_ID=16543" target="_blank">Genetic Testing Registry (GTR)</a>.</p><p class="headingAnchor" id="H462460015"><span class="h2">Management</span><span class="headingEndMark"> — </span>Cowden syndrome/PHTS has effects on multiple organ systems and a multidisciplinary treatment team is needed, which includes dedicated genetic counseling. (See  <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">"Genetic testing"</a>.)</p><p>The following management recommendations apply to patients with documented <em>PTEN</em> pathogenic variants as well as for those who fit the clinical diagnostic criteria for Cowden syndrome/PHTS but lack a detected pathogenic variant. It should be noted that these recommendations are based on expert opinion due to the syndromes being too rare to have empiric evidence on which to base recommendations.</p><p class="headingAnchor" id="H232666982"><span class="h3">Cancer surveillance</span><span class="headingEndMark"> — </span>Given the high risk of malignancy, cancer surveillance is the major focus of medical management. We agree with management guidelines from the NCCN (v3.2023) that outline a cancer surveillance program for both males and females with Cowden syndrome/PHTS [<a href="#rid110">110</a>]. In addition to genetic counseling and education regarding the syndrome and possible manifestations, recommendations for all patients include:</p><p class="bulletIndent1"><span class="glyph">●</span>Annual comprehensive physical exam, with particular attention to breast and thyroid, starting at 18 years of age or five years before the youngest age of diagnosis of a component cancer in the family.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Annual thyroid ultrasound starting at age seven; this may also be considered for children at 50 percent risk of inheriting a known familial mutation whose parents wish to delay genetic testing until age 18.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Colonoscopy at age 35 years unless symptomatic or if close relative with colon cancer before age 40; then start 5 to 10 years before the earliest known colorectal cancer in the family. Repeat every five years or more frequently if patient is symptomatic or polyps are noted.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Consider renal ultrasound at age 40 and repeat every one to two years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Annual dermatologic exam is recommended.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Consider psychomotor assessment in children at diagnosis and brain MRI if there are symptoms.</p><p></p><p>Recommendations specifically for females include:</p><p class="bulletIndent1"><span class="glyph">●</span>Breast awareness starting at age 18 years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical breast exam every 6 to 12 months starting at age 25 years or 10 years before the earliest known onset of breast cancer in the family.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Annual mammography and breast MRI screening starting at age 35 years or 10 years before the earliest known breast cancer in the family.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Education regarding endometrial cancer and prompt response to symptoms consistent with endometrial cancer.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Consider random endometrial biopsies every one to two years. Transvaginal ultrasound (TVUS) to screen for endometrial cancer in postmenopausal individuals is insufficiently sensitive or specific to support a positive recommendation; however, it could be considered at the clinician's discretion. TVUS is not recommended for premenopausal individuals.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Discuss options of risk-reducing mastectomy and hysterectomy (at completion of childbearing) and provide counseling regarding all aspects of these procedures.</p><p></p><p>In addition to these recommendations, several other screening tests not specifically endorsed by the NCCN [<a href="#rid110">110</a>] might be considered:</p><p class="bulletIndent1"><span class="glyph">●</span>Some experts recommend considering prophylactic total thyroidectomy in patients that are unable to undergo routine thyroid surveillance or in those found to have thyroid nodules [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Screening for dysplastic gangliocytoma of the cerebellum has been recommended by some, but there is no evidence of improved outcomes with early detection [<a href="#rid112">112</a>]. However, given the increased incidence of dysplastic gangliocytoma of the cerebellum and the nonspecific and insidious symptoms, there should be a low threshold to perform neuroimaging in any patient with Cowden syndrome/PHTS who develops a persistent headache [<a href="#rid113">113</a>]. MRI is the preferred imaging modality, but biopsy may be needed for definitive diagnosis [<a href="#rid114">114</a>].</p><p></p><p>A European group has proposed cancer surveillance guidelines for individuals with PHTS that are fairly similar to our above recommendations, with some small differences [<a href="#rid115">115</a>].</p><p class="headingAnchor" id="H232667011"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>Treatment of the benign and malignant manifestations of Cowden syndrome/PHTS is performed as per usual practice for sporadic occurrence.</p><p>Although a benign entity, resection of a symptomatic or progressive dysplastic gangliocytoma of the cerebellum is usually undertaken, as hydrocephalus with potentially fatal herniation can result from local growth.</p><p>We advise further individualizing colorectal cancer surveillance recommendations based on personal and familial history of the patient. GI polyps should be endoscopically resected given the varied histology, including frequent adenomatous polyps, and the risk for dysplastic change and colorectal cancer. Endoscopic techniques to improve visual differentiation of polyp histology, such as narrow band imaging, should be considered to allow for preferential removal of large polyps (≥1 cm) or those that appear to be adenomatous [<a href="#rid90">90</a>]. (See  <a class="medical medical_review" href="/z/d/html/2577.html" rel="external">"Endoscopic removal of large colon polyps"</a> and  <a class="medical medical_review" href="/z/d/html/2594.html" rel="external">"Overview of colon polyps", section on 'Hamartomatous polyps'</a>.)</p><p>Future treatment options may involve targeting the genetic pathways affected by loss of <em>PTEN</em> gene function. <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">Sirolimus</a> (also known as rapamycin), commonly used for immunosuppression following solid organ transplantation, suppresses cell proliferation by inhibiting the mechanistic (previously called mammalian) target of rapamycin (mTOR). In a mouse model of experimental Cowden syndrome/PHTS, administration of sirolimus led to regression of mucocutaneous lesions and, if administered prior to their development, decreased the occurrence of mucocutaneous lesions [<a href="#rid116">116</a>]. There are also reports of using sirolimus in severely affected pediatric patients with <em>PTEN</em> pathogenic variants [<a href="#rid117">117-121</a>].</p><p>A short pilot trial investigating the use of <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> and its effect on disease progression for patients with Cowden syndrome and other PHTS with documented <em>PTEN</em> pathogenic variants has been completed. [<a href="#rid122">122</a>]. There was some evidence of improvement in cerebellar function and dermatologic findings. Although therapy was well tolerated overall, laboratory abnormalities were common adverse effects. A more recent randomized controlled trial of <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> for neurocognitive symptoms failed to show significant benefit in primary cognitive or behavioral outcomes [<a href="#rid123">123</a>]. It is clear that further data are needing regarding this potential therapy prior to widespread usage.</p><p class="headingAnchor" id="H3876020749"><span class="h1">OTHER LESS COMMON PHENOTYPES</span></p><p class="headingAnchor" id="H462460023"><span class="h2">Bannayan-Riley-Ruvalcaba syndrome</span><span class="headingEndMark"> — </span>Bannayan-Riley-Ruvalcaba syndrome (BRRS; previously referred to as Ruvalcaba-Myhre syndrome, Ruvalcaba-Myhre-Smith syndrome, Riley-Smith syndrome, Bannayan syndrome, or Bannayan-Zonana syndrome [<a href="#rid124">124</a>]) is a rare autosomal dominant disorder that is caused by germline <em>PTEN</em> pathogenic variants [<a href="#rid125">125</a>]. <em>PTEN</em> mutations are present in 55 to 60 percent of patients with a clinical diagnosis [<a href="#rid1">1,23</a>]. Clinical manifestations arise early in childhood, one aspect that can be different from Cowden syndrome. Evaluation is often started in the first few years of life, with a reported median age of diagnosis as young as five years [<a href="#rid126">126</a>]. Given that identical <em>PTEN</em> pathogenic variants have been described in families with BRRS or Cowden syndrome only [<a href="#rid127">127</a>], and the partial clinical overlap, Cowden syndrome and BRRS are considered variable phenotypic presentations of the same syndrome.</p><p class="headingAnchor" id="H462460040"><span class="h3">Clinical manifestations</span><span class="headingEndMark"> — </span>Clinical diagnostic criteria have not been established for BRRS. As with other phenotypes of PHTS, published data on clinical manifestations come mainly from small case series or compilations of published cases. As a result, the true frequencies of the clinical features are not clearly known [<a href="#rid41">41</a>]. (See <a class="local">'Diagnostic criteria'</a> above.)</p><p>Widely noted clinical findings include [<a href="#rid74">74,101,128</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Macrocephaly (at least two standard deviations above the mean)</p><p class="bulletIndent1"><span class="glyph">●</span>Penile lentigines (a very characteristic marker of the disease [<a href="#rid129">129</a>])  (<a class="graphic graphic_picture graphicRef62253" href="/z/d/graphic/62253.html" rel="external">picture 1</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>GI tract hamartomatous polyps</p><p class="bulletIndent1"><span class="glyph">●</span>Lipomas</p><p class="bulletIndent1"><span class="glyph">●</span>Vascular anomalies including arteriovenous shunts and fistulae [<a href="#rid130">130</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Intramuscular lesions with a mixture of adipose tissue, fibrous tissue, and abnormal vessels (labeled a PTEN hamartoma of soft tissue [<a href="#rid131">131</a>])</p><p class="bulletIndent1"><span class="glyph">●</span>Hashimoto thyroiditis and other thyroid disorders including thyroid cancer</p><p class="bulletIndent1"><span class="glyph">●</span>Mild-to-severe developmental delay or intellectual disability</p><p class="bulletIndent1"><span class="glyph">●</span>Proximal muscle myopathy</p><p class="bulletIndent1"><span class="glyph">●</span>High palate</p><p class="bulletIndent1"><span class="glyph">●</span>Joint hypermobility</p><p class="bulletIndent1"><span class="glyph">●</span>Eye abnormalities such as downslanting palpebral fissures, strabismus, and amblyopia</p><p></p><p>An increased risk of internal malignancy has not been consistently documented with BRRS, although several childhood onset non-medullary thyroid cancers have been reported [<a href="#rid4">4,71,74,75</a>], as well as renal cell cancer and granulosa cell tumor of the ovary [<a href="#rid132">132</a>]. Multiple other clinical findings, such as facial dysmorphology and ophthalmologic abnormalities, have been reported but are less consistently described [<a href="#rid133">133</a>].</p><p>The differential diagnosis includes CLOVE syndrome (congenital lipomatous overgrowth, vascular malformations, and epidermal nevi) [<a href="#rid134">134,135</a>].</p><p class="headingAnchor" id="H2759239434"><span class="h3">Neuroimaging features</span><span class="headingEndMark"> — </span>The main neuroimaging findings of BRRS include macrocephaly, dilated perivascular spaces, and excess spinal fat in soft tissues, epidural space, and bone marrow [<a href="#rid92">92</a>].</p><p class="headingAnchor" id="H462460048"><span class="h3">Management</span><span class="headingEndMark"> — </span>The clinical scoring system noted above for Cowden syndrome/PHTS is also used to select patients with suspected BRRS for germline <em>PTEN</em> testing [<a href="#rid23">23,48</a>]. (See <a class="local">'Diagnostic criteria'</a> above and <a class="local">'Testing criteria'</a> above.)</p><p>BRRS has effects in multiple organ systems, and a multidisciplinary treatment team is needed, including dedicated genetic counseling. (See  <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">"Genetic testing"</a>.)</p><p>Treatments for symptomatic manifestations should follow standard practices.</p><p>There are no consensus guidelines for cancer surveillance in patients with BRRS. We recommend following the complete Cowden syndrome/PHTS cancer surveillance recommendations if a <em>PTEN</em> pathogenic variant is present, given the significant link between this genetic abnormality and cancer risk, and suggest also following these guidelines if clinical manifestations are consistent with the syndrome but a <em>PTEN</em> pathogenic variant is not documented. (See <a class="local">'Cancer surveillance'</a> above.)</p><p class="headingAnchor" id="H462460056"><span class="h2">Proteus-like syndrome</span><span class="headingEndMark"> — </span>There have been previous reports of <em>PTEN</em> pathogenic variants in some patients with phenotypic similarities to the Proteus syndrome. (See  <a class="medical medical_review" href="/z/d/html/13726.html" rel="external">"Capillary malformations (port wine birthmarks) and associated syndromes", section on 'Proteus syndrome'</a>.)</p><p>This has been termed Proteus-like syndrome by some [<a href="#rid8">8,136-139</a>], but differences have now been established and it is <strong>not</strong> felt that germline <em>PTEN</em> pathogenic variants are a cause of typical Proteus syndrome [<a href="#rid139">139,140</a>]. Somatic activating mutations in the v-akt murine thymoma viral oncogene homolog 1 (<em>AKT1</em>) oncogene have been delineated as the genetic cause of Proteus syndrome [<a href="#rid141">141</a>]; all cases are sporadic.</p><p>Proteus-like manifestations in patients with <em>PTEN</em> germline pathogenic variants have been demonstrated to be caused by a second, mosaic <em>PTEN</em> pathogenic variant that occurred during very early embryogenesis in the affected tissues such that lesions may follow lines of Blaschko at times [<a href="#rid9">9,10</a>]. This has led to the recommendation that patients with phenotypic features suggestive of Proteus syndrome but with <em>PTEN</em> pathogenic variants be labeled as having segmental overgrowth, lipomatosis, arteriovenous malformation, and epidermal nevus (SOLAMEN) syndrome [<a href="#rid10">10</a>]. However, if the epidermal nevus is the only finding, then the term linear Cowden nevus, linear PTEN nevus, or type 2 segmental Cowden disease may be more accurately descriptive.</p><p class="headingAnchor" id="H462460064"><span class="h2">Autism spectrum disorders and macrocephaly</span><span class="headingEndMark"> — </span>Autism spectrum disorders (ASD) or developmental delay (DD) with macrocephaly and without other signs of a PHTS are associated with germline <em>PTEN</em> pathogenic variants in 1 to 8 percent of patients [<a href="#rid142">142-144</a>]. Initial work has suggested that this phenotype may relate to differences in functional outcomes of <em>PTEN</em> pathogenic variants [<a href="#rid145">145</a>]. One prospective series that specifically excluded patients with PHTS found mutations in 3 of 18 (17 percent) patients with ASD and extreme macrocephaly [<a href="#rid11">11</a>]. In addition, a novel homozygous <em>PTEN</em> pathogenic variant was reported in siblings with severe macrocephaly and mild intellectual disability but no other PHTS features [<a href="#rid146">146</a>]. A study of 481 patients with germline <em>PTEN</em> pathogenic variants found an increased rate of copy number variants (CNVs) throughout the genome in those patients with ASD/DD (10 percent) compared with patients without ASD/DD (2.6 percent) and patients with cancer (1.7 percent), suggesting that CNVs may modify the phenotype of germline <em>PTEN</em> pathogenic variants [<a href="#rid147">147</a>]. The clinical significance of this finding is unknown, however. At present, American College of Medical Genetics and Genomics guidelines recommend genetic testing for <em>PTEN</em> pathogenic variants in individuals with ASD and a head circumference above the 98<sup>th</sup> percentile [<a href="#rid148">148</a>]. (See  <a class="medical medical_review" href="/z/d/html/628.html" rel="external">"Autism spectrum disorder in children and adolescents: Evaluation and diagnosis"</a>.)</p><p>Although the reports cited above describe patients with <em>PTEN</em> pathogenic variants who do not meet criteria for a clinical diagnosis of PHTS, they do not describe the clinical outcomes of these patients or comment on the development of PHTS when these subjects reach adulthood. Autism and macrocephaly arise early in life and may be childhood manifestations of PHTS rather than a discrete phenotype. Long-term follow-up of these patients will be needed to determine their risk for development of other manifestations and especially malignancies. Until this is clarified, if a <em>PTEN</em> pathogenic variant is detected, it is reasonable to follow the National Comprehensive Cancer Network (NCCN) screening recommendations for Cowden syndrome/PHTS. (See <a class="local">'Testing criteria'</a> above and <a class="local">'Diagnostic criteria'</a> above and  <a class="medical medical_review" href="/z/d/html/2849.html" rel="external">"Macrocephaly in infants and children: Etiology and evaluation", section on 'Anatomic megalencephaly'</a>.)</p><p class="headingAnchor" id="H462460072"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics</strong> <strong>and phenotypic spectrum of PTEN hamartoma tumor syndrome</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Germline pathogenic variants in the phosphatase and tensin homolog (<em>PTEN</em>) gene are described in a variety of rare syndromes with different clinical presentations that are collectively known as PTEN hamartoma tumor syndromes (PHTS).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The defining clinical feature of PHTS is the presence of hamartomatous tumors, which are disorganized growths of native cells in native tissues. PHTS are inherited in an autosomal dominant fashion and have an increased risk of both benign and malignant tumors. (See <a class="local">'Phenotypic spectrum of PHTS'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cowden syndrome</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Definition, diagnosis, and treatment</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Cowden syndrome is the best-described phenotype; it is characterized by mucocutaneous lesions and an elevated risk of breast, thyroid, endometrial, colorectal, and renal cancers as well as various benign manifestations such as macrocephaly and dysplastic gangliocytoma of the cerebellum. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Updated clinical diagnostic criteria for Cowden syndrome/PHTS are available  (<a class="graphic graphic_table graphicRef91666" href="/z/d/graphic/91666.html" rel="external">table 1</a>), as are proposed criteria for genetic testing for <em>PTEN</em> pathogenic variants  (<a class="graphic graphic_table graphicRef72070" href="/z/d/graphic/72070.html" rel="external">table 2</a>). (See <a class="local">'Diagnostic criteria'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Treatment of the benign and malignant manifestations of Cowden syndrome is performed as per usual practice for sporadic occurrence. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cancer screening</strong> – A major focus of management of individuals with Cowden syndrome is on cancer surveillance (see <a class="local">'Cancer surveillance'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We recommend annual comprehensive physical exam, annual thyroid ultrasound from age seven, colonoscopy at least every five years starting at age 35, and annual renal ultrasound starting at age 40.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Women should undergo biannual or annual clinical breast exam at age 25 and annual mammography and breast magnetic resonance imaging at age 35. In addition, endometrial cancer surveillance with blind biopsies beginning at age 35, or five years younger than the earliest familial endometrial cancer diagnosis, for premenopausal women and annual transvaginal ultrasound examination for postmenopausal women can be considered.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We do not recommend screening for brain tumors. However, given the increased incidence of dysplastic gangliocytoma of the cerebellum and the nonspecific and insidious symptoms, there should be a high index of suspicion in patients who meet criteria for Cowden syndrome, and a low threshold to perform neuroimaging in any patient with Cowden syndrome who develops a persistent headache.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bannayan-Riley-Ruvalcaba syndrome (BRRS)</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>BRRS is characterized by macrocephaly, penile lentigines, lipomas, vascular abnormalities, hamartomatous gastrointestinal polyps, and developmental delay. In contrast to Cowden syndrome, clinical diagnostic criteria have not been established for BRRS. (See <a class="local">'Bannayan-Riley-Ruvalcaba syndrome'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Given the effects in multiple organ systems, a multidisciplinary treatment team is needed, including dedicated genetic counseling. We recommend following the cancer surveillance protocol for Cowden syndrome in patients who have a documented <em>PTEN</em> pathogenic variant or a clinical diagnosis of BRRS. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other syndromes</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Several other syndromes are linked with <em>PTEN</em> pathogenic variants, including Proteus-like (segmental overgrowth, lipomatosis, arteriovenous malformation, and epidermal nevus [SOLAMEN]) syndrome and autism spectrum disorder with macrocephaly.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>It is unclear if these conditions have a similarly elevated risk of malignancy, but if a <em>PTEN</em> pathogenic variant is found, it is reasonable to use the recommended cancer surveillance for Cowden syndrome/PHTS. (See <a class="local">'Proteus-like syndrome'</a> above and <a class="local">'Autism spectrum disorders and macrocephaly'</a> above.)</p><p></p><p class="headingAnchor" id="H3971617005"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Mrinal Patnaik, MD, Noralane M Lindor, MD, and Brandie Leach, MS, CGC, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Marsh DJ, Kum JB, Lunetta KL, et al. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet 1999; 8:1461.</a></li><li><a class="nounderline abstract_t">Lachlan KL, Lucassen AM, Bunyan D, Temple IK. Cowden syndrome and Bannayan Riley Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: results of a clinical study of PTEN mutation carriers. J Med Genet 2007; 44:579.</a></li><li><a class="nounderline abstract_t">Marsh DJ, Coulon V, Lunetta KL, et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 1998; 7:507.</a></li><li><a class="nounderline abstract_t">Zori RT, Marsh DJ, Graham GE, et al. Germline PTEN mutation in a family with Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome. Am J Med Genet 1998; 80:399.</a></li><li><a class="nounderline abstract_t">Wanner M, Celebi JT, Peacocke M. Identification of a PTEN mutation in a family with Cowden syndrome and Bannayan-Zonana syndrome. J Am Acad Dermatol 2001; 44:183.</a></li><li><a class="nounderline abstract_t">Zhou XP, Marsh DJ, Morrison CD, et al. Germline inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults. Am J Hum Genet 2003; 73:1191.</a></li><li><a class="nounderline abstract_t">Abel TW, Baker SJ, Fraser MM, et al. Lhermitte-Duclos disease: a report of 31 cases with immunohistochemical analysis of the PTEN/AKT/mTOR pathway. J Neuropathol Exp Neurol 2005; 64:341.</a></li><li><a class="nounderline abstract_t">Zhou X, Hampel H, Thiele H, et al. Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet 2001; 358:210.</a></li><li><a class="nounderline abstract_t">Happle R. Linear Cowden nevus: a new distinct epidermal nevus. Eur J Dermatol 2007; 17:133.</a></li><li><a class="nounderline abstract_t">Caux F, Plauchu H, Chibon F, et al. Segmental overgrowth, lipomatosis, arteriovenous malformation and epidermal nevus (SOLAMEN) syndrome is related to mosaic PTEN nullizygosity. Eur J Hum Genet 2007; 15:767.</a></li><li><a class="nounderline abstract_t">Butler MG, Dasouki MJ, Zhou XP, et al. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet 2005; 42:318.</a></li><li><a class="nounderline abstract_t">LLOYD KM 2nd, DENNIS M. Cowden's disease. A possible new symptom complex with multiple system involvement. Ann Intern Med 1963; 58:136.</a></li><li><a class="nounderline abstract_t">Starink TM, van der Veen JP, Arwert F, et al. The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet 1986; 29:222.</a></li><li><a class="nounderline abstract_t">Weary PE, Gorlin RJ, Gentry WC Jr, et al. Multiple hamartoma syndrome (Cowden's disease). Arch Dermatol 1972; 106:682.</a></li><li><a class="nounderline abstract_t">Mester J, Eng C. Estimate of de novo mutation frequency in probands with PTEN hamartoma tumor syndrome. Genet Med 2012; 14:819.</a></li><li><a class="nounderline abstract_t">Nelen MR, Kremer H, Konings IB, et al. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet 1999; 7:267.</a></li><li><a class="nounderline abstract_t">Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95:29.</a></li><li><a class="nounderline abstract_t">Nelen MR, Padberg GW, Peeters EA, et al. Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet 1996; 13:114.</a></li><li><a class="nounderline abstract_t">Keniry M, Parsons R. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008; 27:5477.</a></li><li><a class="nounderline abstract_t">Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22:2954.</a></li><li><a class="nounderline abstract_t">Krymskaya VP, Goncharova EA. PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects. Cell Cycle 2009; 8:403.</a></li><li><a class="nounderline abstract_t">Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997; 16:64.</a></li><li><a class="nounderline abstract_t">Pilarski R, Stephens JA, Noss R, et al. Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features. J Med Genet 2011; 48:505.</a></li><li><a class="nounderline abstract_t">Tan MH, Mester J, Peterson C, et al. A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am J Hum Genet 2011; 88:42.</a></li><li><a class="nounderline abstract_t">Black MH, Li S, Pesaran T, et al. PTEN Promoter Variants Are Not Associated With Common Cancers: Implications for Multigene Panel Testing. JCO Precis Oncol 2017; 1:1.</a></li><li><a class="nounderline abstract_t">Mester JL, Hruska KS. With Regard to PTEN Promoter Testing for Hereditary Cancer Risk Assessment. JCO Precis Oncol 2018; 2:1.</a></li><li><a class="nounderline abstract_t">Bennett KL, Mester J, Eng C. Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome. JAMA 2010; 304:2724.</a></li><li><a class="nounderline abstract_t">Cho YJ, Liang P. Killin is a p53-regulated nuclear inhibitor of DNA synthesis. Proc Natl Acad Sci U S A 2008; 105:5396.</a></li><li><a class="nounderline abstract_t">Chibon F, Primois C, Bressieux JM, et al. Contribution of PTEN large rearrangements in Cowden disease: a multiplex amplifiable probe hybridisation (MAPH) screening approach. J Med Genet 2008; 45:657.</a></li><li><a class="nounderline abstract_t">Zhou XP, Waite KA, Pilarski R, et al. Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am J Hum Genet 2003; 73:404.</a></li><li><a class="nounderline abstract_t">Ni Y, Zbuk KM, Sadler T, et al. Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes. Am J Hum Genet 2008; 83:261.</a></li><li><a class="nounderline abstract_t">Bayley JP. Succinate dehydrogenase gene variants and their role in Cowden syndrome. Am J Hum Genet 2011; 88:674.</a></li><li><a class="nounderline abstract_t">Orloff MS, He X, Peterson C, et al. Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes. Am J Hum Genet 2013; 92:76.</a></li><li><a class="nounderline abstract_t">Yehia L, Niazi F, Ni Y, et al. Germline Heterozygous Variants in SEC23B Are Associated with Cowden Syndrome and Enriched in Apparently Sporadic Thyroid Cancer. Am J Hum Genet 2015; 97:661.</a></li><li><a class="nounderline abstract_t">Colby S, Yehia L, Niazi F, et al. Exome sequencing reveals germline gain-of-function EGFR mutation in an adult with Lhermitte-Duclos disease. Cold Spring Harb Mol Case Stud 2016; 2:a001230.</a></li><li><a class="nounderline abstract_t">Lee YR, Chen M, Lee JD, et al. Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway. Science 2019; 364.</a></li><li><a class="nounderline abstract_t">Lee YR, Yehia L, Kishikawa T, et al. WWP1 Gain-of-Function Inactivation of PTEN in Cancer Predisposition. N Engl J Med 2020; 382:2103.</a></li><li><a class="nounderline abstract_t">Tan MH, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012; 18:400.</a></li><li><a class="nounderline abstract_t">Bubien V, Bonnet F, Brouste V, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet 2013; 50:255.</a></li><li><a class="nounderline abstract_t">Riegert-Johnson DL, Gleeson FC, Roberts M, et al. Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients. Hered Cancer Clin Pract 2010; 8:6.</a></li><li><a class="nounderline abstract_t">Pilarski R. Cowden syndrome: a critical review of the clinical literature. J Genet Couns 2009; 18:13.</a></li><li><a class="nounderline abstract_t">Ngeow J, Stanuch K, Mester JL, et al. Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations. J Clin Oncol 2014; 32:1818.</a></li><li><a class="nounderline abstract_t">Hildenbrand C, Burgdorf WH, Lautenschlager S. Cowden syndrome-diagnostic skin signs. Dermatology 2001; 202:362.</a></li><li><a class="nounderline abstract_t">Salem OS, Steck WD. Cowden's disease (multiple hamartoma and neoplasia syndrome). A case report and review of the English literature. J Am Acad Dermatol 1983; 8:686.</a></li><li><a class="nounderline abstract_t">Heald B, Mester J, Rybicki L, et al. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology 2010; 139:1927.</a></li><li><a class="nounderline abstract_t">Brownstein MH, Mehregan AH, Bikowski JB, et al. The dermatopathology of Cowden's syndrome. Br J Dermatol 1979; 100:667.</a></li><li><a class="nounderline abstract_t">Tellechea O, Cardoso JC, Reis JP, et al. Benign follicular tumors. An Bras Dermatol 2015; 90:780.</a></li><li><a class="nounderline abstract_t">Pilarski R, Burt R, Kohlman W, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst 2013; 105:1607.</a></li><li><a class="nounderline abstract_t">Al-Zaid T, Ditelberg JS, Prieto VG, et al. Trichilemmomas show loss of PTEN in Cowden syndrome but only rarely in sporadic tumors. J Cutan Pathol 2012; 39:493.</a></li><li><a class="nounderline abstract_t">Masmoudi A, Chermi ZM, Marrekchi S, et al. Cowden syndrome. J Dermatol Case Rep 2011; 5:8.</a></li><li><a class="nounderline abstract_t">Hanssen AM, Werquin H, Suys E, Fryns JP. Cowden syndrome: report of a large family with macrocephaly and increased severity of signs in subsequent generations. Clin Genet 1993; 44:281.</a></li><li><a class="nounderline abstract_t">Potenziani S, Applebaum D, Krishnan B, et al. Multiple clear cell acanthomas and a sebaceous lymphadenoma presenting in a patient with Cowden syndrome - a case report. J Cutan Pathol 2017; 44:79.</a></li><li><a class="nounderline abstract_t">Ponti G, Nasti S, Losi L, et al. Brooke-Spiegler syndrome: report of two cases not associated with a mutation in the CYLD and PTCH tumor-suppressor genes. J Cutan Pathol 2012; 39:366.</a></li><li><a class="nounderline abstract_t">Longy M, Lacombe D. Cowden disease. Report of a family and review. Ann Genet 1996; 39:35.</a></li><li><a class="nounderline abstract_t">Reifenberger J, Rauch L, Beckmann MW, et al. Cowden's disease: clinical and molecular genetic findings in a patient with a novel PTEN germline mutation. Br J Dermatol 2003; 148:1040.</a></li><li><a class="nounderline abstract_t">Yehia L, Plitt G, Tushar AM, et al. Longitudinal Analysis of Cancer Risk in Children and Adults With Germline PTEN Variants. JAMA Netw Open 2023; 6:e239705.</a></li><li><a class="nounderline abstract_t">Nieuwenhuis MH, Kets CM, Murphy-Ryan M, et al. Cancer risk and genotype-phenotype correlations in PTEN hamartoma tumor syndrome. Fam Cancer 2014; 13:57.</a></li><li><a class="nounderline abstract_t">FitzGerald MG, Marsh DJ, Wahrer D, et al. Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer. Oncogene 1998; 17:727.</a></li><li><a class="nounderline abstract_t">Tung N, Battelli C, Allen B, et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer 2015; 121:25.</a></li><li><a class="nounderline abstract_t">Schrager CA, Schneider D, Gruener AC, et al. Clinical and pathological features of breast disease in Cowden's syndrome: an underrecognized syndrome with an increased risk of breast cancer. Hum Pathol 1998; 29:47.</a></li><li><a class="nounderline abstract_t">Hendricks LAJ, Hoogerbrugge N, Schuurs-Hoeijmakers JHM, Vos JR. A review on age-related cancer risks in PTEN hamartoma tumor syndrome. Clin Genet 2021; 99:219.</a></li><li><a class="nounderline abstract_t">Fackenthal JD, Marsh DJ, Richardson AL, et al. Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet 2001; 38:159.</a></li><li><a class="nounderline abstract_t">Gustafson S, Zbuk KM, Scacheri C, Eng C. Cowden syndrome. Semin Oncol 2007; 34:428.</a></li><li><a class="nounderline abstract_t">Patnaik MM, Raza SS, Khambatta S, et al. Oncophenotypic review and clinical correlates of phosphatase and tensin homolog on chromosome 10 hamartoma tumor syndrome. J Clin Oncol 2010; 28:e767.</a></li><li><a class="nounderline abstract_t">Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol 2015; 33:304.</a></li><li><a class="nounderline abstract_t">Banneau G, Guedj M, MacGrogan G, et al. Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations. Breast Cancer Res 2010; 12:R63.</a></li><li><a class="nounderline abstract_t">Peiró G, Adrover E, Guijarro J, et al. Synchronous bilateral breast carcinoma in a patient with cowden syndrome: a case report with morphologic, immunohistochemical and genetic analysis. Breast J 2010; 16:77.</a></li><li><a class="nounderline abstract_t">Sabaté JM, Gómez A, Torrubia S, et al. Evaluation of breast involvement in relation to Cowden syndrome: a radiological and clinicopathological study of patients with PTEN germ-line mutations. Eur Radiol 2006; 16:702.</a></li><li><a class="nounderline abstract_t">Hall JE, Abdollahian DJ, Sinard RJ. Thyroid disease associated with Cowden syndrome: A meta-analysis. Head Neck 2013; 35:1189.</a></li><li><a class="nounderline abstract_t">Harach HR, Soubeyran I, Brown A, et al. Thyroid pathologic findings in patients with Cowden disease. Ann Diagn Pathol 1999; 3:331.</a></li><li><a class="nounderline abstract_t">Laury AR, Bongiovanni M, Tille JC, et al. Thyroid pathology in PTEN-hamartoma tumor syndrome: characteristic findings of a distinct entity. Thyroid 2011; 21:135.</a></li><li><a class="nounderline abstract_t">Ngeow J, Mester J, Rybicki LA, et al. Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations. J Clin Endocrinol Metab 2011; 96:E2063.</a></li><li><a class="nounderline abstract_t">Milas M, Mester J, Metzger R, et al. Should patients with Cowden syndrome undergo prophylactic thyroidectomy? Surgery 2012; 152:1201.</a></li><li><a class="nounderline abstract_t">Tan WH, Baris HN, Burrows PE, et al. The spectrum of vascular anomalies in patients with PTEN mutations: implications for diagnosis and management. J Med Genet 2007; 44:594.</a></li><li><a class="nounderline abstract_t">Smith JR, Marqusee E, Webb S, et al. Thyroid nodules and cancer in children with PTEN hamartoma tumor syndrome. J Clin Endocrinol Metab 2011; 96:34.</a></li><li><a class="nounderline abstract_t">Woodhouse J, Ferguson MM. Multiple hyperechoic testicular lesions are a common finding on ultrasound in Cowden disease and represent lipomatosis of the testis. Br J Radiol 2006; 79:801.</a></li><li><a class="nounderline abstract_t">Woodhouse JB, Delahunt B, English SF, et al. Testicular lipomatosis in Cowden's syndrome. Mod Pathol 2005; 18:1151.</a></li><li><a class="nounderline abstract_t">Alnajjar HM, Sahai A, Keane A, Gordon S. Testicular pain as a presentation of Cowden syndrome. Ann R Coll Surg Engl 2011; 93:e51.</a></li><li><a class="nounderline abstract_t">Baker WD, Soisson AP, Dodson MK. Endometrial cancer in a 14-year-old girl with Cowden syndrome: a case report. J Obstet Gynaecol Res 2013; 39:876.</a></li><li><a class="nounderline abstract_t">Mester JL, Zhou M, Prescott N, Eng C. Papillary renal cell carcinoma is associated with PTEN hamartoma tumor syndrome. Urology 2012; 79:1187.e1.</a></li><li><a class="nounderline abstract_t">Modi RM, Arnold CA, Stanich PP. Diffuse Esophageal Glycogenic Acanthosis and Colon Polyposis in a Patient With Cowden Syndrome. Clin Gastroenterol Hepatol 2017; 15:e131.</a></li><li><a class="nounderline abstract_t">Levi Z, Baris HN, Kedar I, et al. Upper and Lower Gastrointestinal Findings in PTEN Mutation-Positive Cowden Syndrome Patients Participating in an Active Surveillance Program. Clin Transl Gastroenterol 2011; 2:e5.</a></li><li><a class="nounderline abstract_t">Kato M, Mizuki A, Hayashi T, et al. Cowden's disease diagnosed through mucocutaneous lesions and gastrointestinal polyposis with recurrent hematochezia, unrevealed by initial diagnosis. Intern Med 2000; 39:559.</a></li><li><a class="nounderline abstract_t">Isomoto H, Furusu H, Ohnita K, et al. Effect of Helicobacter pylori eradication on gastric hyperplastic polyposis in Cowden's disease. World J Gastroenterol 2005; 11:1567.</a></li><li><a class="nounderline abstract_t">Hamby LS, Lee EY, Schwartz RW. Parathyroid adenoma and gastric carcinoma as manifestations of Cowden's disease. Surgery 1995; 118:115.</a></li><li><a class="nounderline abstract_t">Al-Thihli K, Palma L, Marcus V, et al. A case of Cowden's syndrome presenting with gastric carcinomas and gastrointestinal polyposis. Nat Clin Pract Gastroenterol Hepatol 2009; 6:184.</a></li><li><a class="nounderline abstract_t">de Leon MP, Di Gregorio C, Giunti L, et al. Duodenal carcinoma in a 37-year-old man with Cowden/Bannayan syndrome. Dig Liver Dis 2013; 45:75.</a></li><li><a class="nounderline abstract_t">Stanich PP, Owens VL, Sweetser S, et al. Colonic polyposis and neoplasia in Cowden syndrome. Mayo Clin Proc 2011; 86:489.</a></li><li><a class="nounderline abstract_t">Khare A, Burke CA, Heald B, et al. Endoscopic Findings in Patients With PTEN Hamartoma Tumor Syndrome Undergoing Surveillance. J Clin Gastroenterol 2022; 56:e183.</a></li><li><a class="nounderline abstract_t">Levi Z, Baris HN, Kedar I, et al. Upper and Lower Gastrointestinal Findings in PTEN Mutation-Positive Cowden Syndrome Patients Participating in an Active Surveillance Program. Clin Transl Gastroenterol 2011; 2:e5.</a></li><li><a class="nounderline abstract_t">Nieuwenhuis MH, Kets CM, Murphy-Ryan M, et al. Is colorectal surveillance indicated in patients with PTEN mutations? Colorectal Dis 2012; 14:e562.</a></li><li><a class="nounderline abstract_t">Zamary AR, Mamlouk MD. Neuroimaging features of genetic syndromes associated with CNS overgrowth. Pediatr Radiol 2022; 52:2452.</a></li><li><a class="nounderline abstract_t">Dhamija R, Hoxworth JM. Imaging of PTEN-related abnormalities in the central nervous system. Clin Imaging 2020; 60:180.</a></li><li><a class="nounderline abstract_t">Lok C, Viseux V, Avril MF, et al. Brain magnetic resonance imaging in patients with Cowden syndrome. Medicine (Baltimore) 2005; 84:129.</a></li><li><a class="nounderline abstract_t">Nowak DA, Trost HA. Lhermitte-Duclos disease (dysplastic cerebellar gangliocytoma): a malformation, hamartoma or neoplasm? Acta Neurol Scand 2002; 105:137.</a></li><li><a class="nounderline abstract_t">Vinchon M, Blond S, Lejeune JP, et al. Association of Lhermitte-Duclos and Cowden disease: report of a new case and review of the literature. J Neurol Neurosurg Psychiatry 1994; 57:699.</a></li><li class="breakAll">Yehia L, Eng C. PTEN Hamartoma Tumor Syndrome. 2001 Nov 29 [Updated 2021 Feb 11]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2021.  Available online at: https://www.ncbi.nlm.nih.gov/books/NBK1488/ (Accessed on May 06, 2021).</li><li><a class="nounderline abstract_t">Robinson S, Cohen AR. Cowden disease and Lhermitte-Duclos disease: characterization of a new phakomatosis. Neurosurgery 2000; 46:371.</a></li><li><a class="nounderline abstract_t">Prats-Sánchez LA, Hervás-García JV, Becerra JL, et al. Multiple Intracranial Arteriovenous Fistulas in Cowden Syndrome. J Stroke Cerebrovasc Dis 2016; 25:e93.</a></li><li><a class="nounderline abstract_t">Mester JL, Tilot AK, Rybicki LA, et al. Analysis of prevalence and degree of macrocephaly in patients with germline PTEN mutations and of brain weight in Pten knock-in murine model. Eur J Hum Genet 2011; 19:763.</a></li><li><a class="nounderline abstract_t">Parisi MA, Dinulos MB, Leppig KA, et al. The spectrum and evolution of phenotypic findings in PTEN mutation positive cases of Bannayan-Riley-Ruvalcaba syndrome. J Med Genet 2001; 38:52.</a></li><li><a class="nounderline abstract_t">Goffin A, Hoefsloot LH, Bosgoed E, et al. PTEN mutation in a family with Cowden syndrome and autism. Am J Med Genet 2001; 105:521.</a></li><li><a class="nounderline abstract_t">Conti S, Condò M, Posar A, et al. Phosphatase and tensin homolog (PTEN) gene mutations and autism: literature review and a case report of a patient with Cowden syndrome, autistic disorder, and epilepsy. J Child Neurol 2012; 27:392.</a></li><li><a class="nounderline abstract_t">Di Cristofano A, Kotsi P, Peng YF, et al. Impaired Fas response and autoimmunity in Pten+/- mice. Science 1999; 285:2122.</a></li><li><a class="nounderline abstract_t">Baracho GV, Miletic AV, Omori SA, et al. Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation. Curr Opin Immunol 2011; 23:178.</a></li><li><a class="nounderline abstract_t">Eissing M, Ripken L, Schreibelt G, et al. PTEN Hamartoma Tumor Syndrome and Immune Dysregulation. Transl Oncol 2019; 12:361.</a></li><li><a class="nounderline abstract_t">Taylor H, Laurence ADJ, Uhlig HH. The Role of PTEN in Innate and Adaptive Immunity. Cold Spring Harb Perspect Med 2019; 9.</a></li><li><a class="nounderline abstract_t">Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet 2000; 37:828.</a></li><li><a class="nounderline abstract_t">Pilarski R, Eng C. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J Med Genet 2004; 41:323.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).</li><li><a class="nounderline abstract_t">Ngeow J, Liu C, Zhou K, et al. Detecting Germline PTEN Mutations Among At-Risk Patients With Cancer: An Age- and Sex-Specific Cost-Effectiveness Analysis. J Clin Oncol 2015; 33:2537.</a></li><li><a class="nounderline abstract_t">Robinson S, Cohen AR. Cowden disease and Lhermitte-Duclos disease: an update. Case report and review of the literature. Neurosurg Focus 2006; 20:E6.</a></li><li><a class="nounderline abstract_t">Fistarol SK, Anliker MD, Itin PH. Cowden disease or multiple hamartoma syndrome--cutaneous clue to internal malignancy. Eur J Dermatol 2002; 12:411.</a></li><li><a class="nounderline abstract_t">Huang S, Zhang G, Zhang J. Similar MR imaging characteristics but different pathological changes: a misdiagnosis for Lhermitte-Duclos disease and review of the literature. Int J Clin Exp Pathol 2015; 8:7583.</a></li><li><a class="nounderline abstract_t">Tischkowitz M, Colas C, Pouwels S, et al. Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome. Eur J Hum Genet 2020; 28:1387.</a></li><li><a class="nounderline abstract_t">Squarize CH, Castilho RM, Gutkind JS. Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin. Cancer Res 2008; 68:7066.</a></li><li><a class="nounderline abstract_t">Marsh DJ, Trahair TN, Martin JL, et al. Rapamycin treatment for a child with germline PTEN mutation. Nat Clin Pract Oncol 2008; 5:357.</a></li><li><a class="nounderline abstract_t">Zak M, Ledbetter M, Maertens P. Infantile Lhermitte-Duclos Disease Treated Successfully With Rapamycin. J Child Neurol 2017; 32:322.</a></li><li><a class="nounderline abstract_t">Iacobas I, Burrows PE, Adams DM, et al. Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation. Pediatr Blood Cancer 2011; 57:321.</a></li><li><a class="nounderline abstract_t">Schmid GL, Kässner F, Uhlig HH, et al. Sirolimus treatment of severe PTEN hamartoma tumor syndrome: case report and in vitro studies. Pediatr Res 2014; 75:527.</a></li><li><a class="nounderline abstract_t">Pimpalwar S, Yoo R, Chau A, et al. Temporal Evolution and Management of Fast Flow Vascular Anomalies in PTEN Hamartoma Tumor Syndrome. Int J Angiol 2018; 27:158.</a></li><li><a class="nounderline abstract_t">Komiya T, Blumenthal GM, DeChowdhury R, et al. A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN. Oncologist 2019; 24:1510.</a></li><li><a class="nounderline abstract_t">Srivastava S, Jo B, Zhang B, et al. A randomized controlled trial of everolimus for neurocognitive symptoms in PTEN hamartoma tumor syndrome. Hum Mol Genet 2022; 31:3393.</a></li><li><a class="nounderline abstract_t">Cohen MM Jr. Bannayan-Riley-Ruvalcaba syndrome: renaming three formerly recognized syndromes as one etiologic entity. Am J Med Genet 1990; 35:291.</a></li><li><a class="nounderline abstract_t">Marsh DJ, Dahia PL, Zheng Z, et al. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet 1997; 16:333.</a></li><li><a class="nounderline abstract_t">Lynch NE, Lynch SA, McMenamin J, Webb D. Bannayan-Riley-Ruvalcaba syndrome: a cause of extreme macrocephaly and neurodevelopmental delay. Arch Dis Child 2009; 94:553.</a></li><li><a class="nounderline abstract_t">Bonneau D, Longy M. Mutations of the human PTEN gene. Hum Mutat 2000; 16:109.</a></li><li><a class="nounderline abstract_t">Gorlin RJ, Cohen MM Jr, Condon LM, Burke BA. Bannayan-Riley-Ruvalcaba syndrome. Am J Med Genet 1992; 44:307.</a></li><li><a class="nounderline abstract_t">Hendriks YM, Verhallen JT, van der Smagt JJ, et al. Bannayan-Riley-Ruvalcaba syndrome: further delineation of the phenotype and management of PTEN mutation-positive cases. Fam Cancer 2003; 2:79.</a></li><li><a class="nounderline abstract_t">Litzendorf M, Hoang K, Vaccaro P. Recurrent and extensive vascular malformations in a patient with Bannayan--Riley--Ruvalcaba syndrome. Ann Vasc Surg 2011; 25:1138.e15.</a></li><li><a class="nounderline abstract_t">Kurek KC, Howard E, Tennant LB, et al. PTEN hamartoma of soft tissue: a distinctive lesion in PTEN syndromes. Am J Surg Pathol 2012; 36:671.</a></li><li><a class="nounderline abstract_t">Smpokou P, Fox VL, Tan WH. PTEN hamartoma tumour syndrome: early tumour development in children. Arch Dis Child 2015; 100:34.</a></li><li><a class="nounderline abstract_t">Erkek E, Hizel S, Sanlý C, et al. Clinical and histopathological findings in Bannayan-Riley-Ruvalcaba syndrome. J Am Acad Dermatol 2005; 53:639.</a></li><li><a class="nounderline abstract_t">Alomari AI. Characterization of a distinct syndrome that associates complex truncal overgrowth, vascular, and acral anomalies: a descriptive study of 18 cases of CLOVES syndrome. Clin Dysmorphol 2009; 18:1.</a></li><li><a class="nounderline abstract_t">Sapp JC, Turner JT, van de Kamp JM, et al. Newly delineated syndrome of congenital lipomatous overgrowth, vascular malformations, and epidermal nevi (CLOVE syndrome) in seven patients. Am J Med Genet A 2007; 143A:2944.</a></li><li><a class="nounderline abstract_t">Zhou XP, Marsh DJ, Hampel H, et al. Germline and germline mosaic PTEN mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arteriovenous malformations and lipomatosis. Hum Mol Genet 2000; 9:765.</a></li><li><a class="nounderline abstract_t">Smith JM, Kirk EP, Theodosopoulos G, et al. Germline mutation of the tumour suppressor PTEN in Proteus syndrome. J Med Genet 2002; 39:937.</a></li><li><a class="nounderline abstract_t">Loffeld A, McLellan NJ, Cole T, et al. Epidermal naevus in Proteus syndrome showing loss of heterozygosity for an inherited PTEN mutation. Br J Dermatol 2006; 154:1194.</a></li><li><a class="nounderline abstract_t">Cohen MM Jr, Turner JT, Biesecker LG. Proteus syndrome: misdiagnosis with PTEN mutations. Am J Med Genet A 2003; 122A:323.</a></li><li><a class="nounderline abstract_t">Biesecker LG, Rosenberg MJ, Vacha S, et al. PTEN mutations and proteus syndrome. Lancet 2001; 358:2079.</a></li><li><a class="nounderline abstract_t">Lindhurst MJ, Sapp JC, Teer JK, et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med 2011; 365:611.</a></li><li><a class="nounderline abstract_t">McBride KL, Varga EA, Pastore MT, et al. Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly. Autism Res 2010; 3:137.</a></li><li><a class="nounderline abstract_t">Orrico A, Galli L, Buoni S, et al. Novel PTEN mutations in neurodevelopmental disorders and macrocephaly. Clin Genet 2009; 75:195.</a></li><li><a class="nounderline abstract_t">Buxbaum JD, Cai G, Chaste P, et al. Mutation screening of the PTEN gene in patients with autism spectrum disorders and macrocephaly. Am J Med Genet B Neuropsychiatr Genet 2007; 144B:484.</a></li><li><a class="nounderline abstract_t">Spinelli L, Black FM, Berg JN, et al. Functionally distinct groups of inherited PTEN mutations in autism and tumour syndromes. J Med Genet 2015; 52:128.</a></li><li><a class="nounderline abstract_t">Schwerd T, Khaled AV, Schürmann M, et al. A recessive form of extreme macrocephaly and mild intellectual disability complements the spectrum of PTEN hamartoma tumour syndrome. Eur J Hum Genet 2016; 24:889.</a></li><li><a class="nounderline abstract_t">Yehia L, Seyfi M, Niestroj LM, et al. Copy Number Variation and Clinical Outcomes in Patients With Germline PTEN Mutations. JAMA Netw Open 2020; 3:e1920415.</a></li><li><a class="nounderline abstract_t">Schaefer GB, Mendelsohn NJ, Professional Practice and Guidelines Committee. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. Genet Med 2013; 15:399.</a></li></ol></div><div id="topicVersionRevision">Topic 16543 Version 46.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10400993" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17526800" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cowden syndrome and Bannayan Riley Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: results of a clinical study of PTEN mutation carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9467011" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9856571" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Germline PTEN mutation in a family with Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11174374" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Identification of a PTEN mutation in a family with Cowden syndrome and Bannayan-Zonana syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14566704" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Germline inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15835270" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Lhermitte-Duclos disease: a report of 31 cases with immunohistochemical analysis of the PTEN/AKT/mTOR pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11476841" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17337396" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Linear Cowden nevus: a new distinct epidermal nevus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17392703" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Segmental overgrowth, lipomatosis, arteriovenous malformation and epidermal nevus (SOLAMEN) syndrome is related to mosaic PTEN nullizygosity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15805158" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13931122" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cowden's disease. A possible new symptom complex with multiple system involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3698331" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The Cowden syndrome: a clinical and genetic study in 21 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4635800" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Multiple hamartoma syndrome (Cowden's disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22595938" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Estimate of de novo mutation frequency in probands with PTEN hamartoma tumor syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10234502" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9778245" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8673088" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Localization of the gene for Cowden disease to chromosome 10q22-23.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18794882" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The role of PTEN signaling perturbations in cancer and in targeted therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15254063" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The biology and clinical relevance of the PTEN tumor suppressor pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19177005" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9140396" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21659347" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21194675" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35172517" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : PTEN Promoter Variants Are Not Associated With Common Cancers: Implications for Multigene Panel Testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35135109" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : With Regard to PTEN Promoter Testing for Hereditary Cancer Risk Assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21177507" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18385383" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Killin is a p53-regulated nuclear inhibitor of DNA synthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18456716" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Contribution of PTEN large rearrangements in Cowden disease: a multiplex amplifiable probe hybridisation (MAPH) screening approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12844284" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18678321" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21565294" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Succinate dehydrogenase gene variants and their role in Cowden syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23246288" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26522472" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Germline Heterozygous Variants in SEC23B Are Associated with Cowden Syndrome and Enriched in Apparently Sporadic Thyroid Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27900366" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Exome sequencing reveals germline gain-of-function EGFR mutation in an adult with Lhermitte-Duclos disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31097636" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32459922" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : WWP1 Gain-of-Function Inactivation of PTEN in Cancer Predisposition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22252256" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Lifetime cancer risks in individuals with germline PTEN mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23335809" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20565722" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18972196" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cowden syndrome: a critical review of the clinical literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24778394" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11455162" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cowden syndrome-diagnostic skin signs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6863628" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cowden's disease (multiple hamartoma and neoplasia syndrome). A case report and review of the English literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20600018" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/465314" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The dermatopathology of Cowden's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26734858" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Benign follicular tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24136893" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22486434" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Trichilemmomas show loss of PTEN in Cowden syndrome but only rarely in sporadic tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21886759" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Cowden syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8131297" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Cowden syndrome: report of a large family with macrocephaly and increased severity of signs in subsequent generations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27682856" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Multiple clear cell acanthomas and a sebaceous lymphadenoma presenting in a patient with Cowden syndrome - a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22077640" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Brooke-Spiegler syndrome: report of two cases not associated with a mutation in the CYLD and PTCH tumor-suppressor genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9297442" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Cowden disease. Report of a family and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12786840" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Cowden's disease: clinical and molecular genetic findings in a patient with a novel PTEN germline mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37093598" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Longitudinal Analysis of Cancer Risk in Children and Adults With Germline PTEN Variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23934601" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Cancer risk and genotype-phenotype correlations in PTEN hamartoma tumor syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9715274" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25186627" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9445133" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Clinical and pathological features of breast disease in Cowden's syndrome: an underrecognized syndrome with an increased risk of breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33140411" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A review on age-related cancer risks in PTEN hamartoma tumor syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11238682" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Male breast cancer in Cowden syndrome patients with germline PTEN mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17920899" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Cowden syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21060037" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Oncophenotypic review and clinical correlates of phosphatase and tensin homolog on chromosome 10 hamartoma tumor syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25452441" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20712882" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19968660" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Synchronous bilateral breast carcinoma in a patient with cowden syndrome: a case report with morphologic, immunohistochemical and genetic analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16208511" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Evaluation of breast involvement in relation to Cowden syndrome: a radiological and clinicopathological study of patients with PTEN germ-line mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22431287" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Thyroid disease associated with Cowden syndrome: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10594284" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Thyroid pathologic findings in patients with Cowden disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21190448" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Thyroid pathology in PTEN-hamartoma tumor syndrome: characteristic findings of a distinct entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21956414" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23158187" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Should patients with Cowden syndrome undergo prophylactic thyroidectomy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17526801" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The spectrum of vascular anomalies in patients with PTEN mutations: implications for diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20962022" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Thyroid nodules and cancer in children with PTEN hamartoma tumor syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16980675" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Multiple hyperechoic testicular lesions are a common finding on ultrasound in Cowden disease and represent lipomatosis of the testis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15920539" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Testicular lipomatosis in Cowden's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21943449" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Testicular pain as a presentation of Cowden syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23279635" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Endometrial cancer in a 14-year-old girl with Cowden syndrome: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22381246" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Papillary renal cell carcinoma is associated with PTEN hamartoma tumor syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28013114" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Diffuse Esophageal Glycogenic Acanthosis and Colon Polyposis in a Patient With Cowden Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23238744" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Upper and Lower Gastrointestinal Findings in PTEN Mutation-Positive Cowden Syndrome Patients Participating in an Active Surveillance Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10888212" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Cowden's disease diagnosed through mucocutaneous lesions and gastrointestinal polyposis with recurrent hematochezia, unrevealed by initial diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15770740" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Effect of Helicobacter pylori eradication on gastric hyperplastic polyposis in Cowden's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7604372" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Parathyroid adenoma and gastric carcinoma as manifestations of Cowden's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19190598" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : A case of Cowden's syndrome presenting with gastric carcinomas and gastrointestinal polyposis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23117110" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Duodenal carcinoma in a 37-year-old man with Cowden/Bannayan syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21628613" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Colonic polyposis and neoplasia in Cowden syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34231499" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Endoscopic Findings in Patients With PTEN Hamartoma Tumor Syndrome Undergoing Surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23238744" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Upper and Lower Gastrointestinal Findings in PTEN Mutation-Positive Cowden Syndrome Patients Participating in an Active Surveillance Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22672595" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Is colorectal surveillance indicated in patients with PTEN mutations?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36207456" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Neuroimaging features of genetic syndromes associated with CNS overgrowth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31927175" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Imaging of PTEN-related abnormalities in the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15758842" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Brain magnetic resonance imaging in patients with Cowden syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11886354" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Lhermitte-Duclos disease (dysplastic cerebellar gangliocytoma): a malformation, hamartoma or neoplasm?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8006650" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Association of Lhermitte-Duclos and Cowden disease: report of a new case and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8006650" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Association of Lhermitte-Duclos and Cowden disease: report of a new case and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10690726" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Cowden disease and Lhermitte-Duclos disease: characterization of a new phakomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27105569" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Multiple Intracranial Arteriovenous Fistulas in Cowden Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21343951" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Analysis of prevalence and degree of macrocephaly in patients with germline PTEN mutations and of brain weight in Pten knock-in murine model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11332402" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : The spectrum and evolution of phenotypic findings in PTEN mutation positive cases of Bannayan-Riley-Ruvalcaba syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11496368" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : PTEN mutation in a family with Cowden syndrome and autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21960672" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Phosphatase and tensin homolog (PTEN) gene mutations and autism: literature review and a case report of a patient with Cowden syndrome, autistic disorder, and epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10497129" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Impaired Fas response and autoimmunity in Pten+/- mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21277760" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30504085" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : PTEN Hamartoma Tumor Syndrome and Immune Dysregulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31501268" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : The Role of PTEN in Innate and Adaptive Immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11073535" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Will the real Cowden syndrome please stand up: revised diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15121767" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15121767" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26169622" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Detecting Germline PTEN Mutations Among At-Risk Patients With Cancer: An Age- and Sex-Specific Cost-Effectiveness Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16459996" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Cowden disease and Lhermitte-Duclos disease: an update. Case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12370126" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Cowden disease or multiple hamartoma syndrome--cutaneous clue to internal malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26261673" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Similar MR imaging characteristics but different pathological changes: a misdiagnosis for Lhermitte-Duclos disease and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32533092" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18757421" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18431376" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Rapamycin treatment for a child with germline PTEN mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27932596" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Infantile Lhermitte-Duclos Disease Treated Successfully With Rapamycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21360661" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24366516" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Sirolimus treatment of severe PTEN hamartoma tumor syndrome: case report and in vitro studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30154635" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Temporal Evolution and Management of Fast Flow Vascular Anomalies in PTEN Hamartoma Tumor Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31350329" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35594551" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : A randomized controlled trial of everolimus for neurocognitive symptoms in PTEN hamartoma tumor syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2309773" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Bannayan-Riley-Ruvalcaba syndrome: renaming three formerly recognized syndromes as one etiologic entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9241266" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Germline mutations in PTEN are present in Bannayan-Zonana syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19321504" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Bannayan-Riley-Ruvalcaba syndrome: a cause of extreme macrocephaly and neurodevelopmental delay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10923032" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Mutations of the human PTEN gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1336932" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Bannayan-Riley-Ruvalcaba syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14574156" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Bannayan-Riley-Ruvalcaba syndrome: further delineation of the phenotype and management of PTEN mutation-positive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21856113" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Recurrent and extensive vascular malformations in a patient with Bannayan--Riley--Ruvalcaba syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22446940" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : PTEN hamartoma of soft tissue: a distinctive lesion in PTEN syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25114091" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : PTEN hamartoma tumour syndrome: early tumour development in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16198785" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Clinical and histopathological findings in Bannayan-Riley-Ruvalcaba syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19011570" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Characterization of a distinct syndrome that associates complex truncal overgrowth, vascular, and acral anomalies: a descriptive study of 18 cases of CLOVES syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17963221" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Newly delineated syndrome of congenital lipomatous overgrowth, vascular malformations, and epidermal nevi (CLOVE syndrome) in seven patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10749983" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Germline and germline mosaic PTEN mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arteriovenous malformations and lipomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12471211" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Germline mutation of the tumour suppressor PTEN in Proteus syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16704655" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Epidermal naevus in Proteus syndrome showing loss of heterozygosity for an inherited PTEN mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14518070" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Proteus syndrome: misdiagnosis with PTEN mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11755638" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : PTEN mutations and proteus syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21793738" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : A mosaic activating mutation in AKT1 associated with the Proteus syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20533527" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18759867" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Novel PTEN mutations in neurodevelopmental disorders and macrocephaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17427195" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Mutation screening of the PTEN gene in patients with autism spectrum disorders and macrocephaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25527629" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Functionally distinct groups of inherited PTEN mutations in autism and tumour syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26443266" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : A recessive form of extreme macrocephaly and mild intellectual disability complements the spectrum of PTEN hamartoma tumour syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32003824" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Copy Number Variation and Clinical Outcomes in Patients With Germline PTEN Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23519317" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
